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BACKGROUND. DiminishedexpressionofRaf kinase inhibitor protein (RKIP), an inhibitor of
the Raf signaling cascade, promotes prostate cancer (PCa) metastasis in a murine model,
suggesting that it is ametastasis suppressor gene.However, the prognostic significance of RKIP
expression and its association with metastasis in PCa patients is unknown.
METHODS. To investigate RKIP protein expression is a prognostic marker in PCa we
performed immunohistochemical staining for RKIP expression in tissuemicroarrays consisting
of 758 non-neoplastic prostate tissues, primary tumors and metastases from 134 PCa patients.
TheCox proportional-hazardsmodelwas used to adjust for covariates includingGleason score,
tumor volume, tumor weight, clinical stage, digital rectal exam findings, serum PSA level and
surgical margins.
RESULTS. RKIP expression was low in approximately 5%, 48%, and 89%of non-neoplastic
prostate, primary tumors andmetastases, respectively. LowRKIPexpression inprimary tumors
was a strong positive predictive factor for PCa recurrence based on PSA levels. In patients
whose primary tumors expressed high RKIP levels, the 7-year PSA recurrence rate was <10%;
whereas in patients with tumors with low RKIP expression the recurrence rate was 50%
(P< 0.001). Multivariate analysis revealed RKIP was an independent prognostic factor
(P< 0.001).
CONCLUSION. In contrast to increased expression of pro-tumorigenic genes, these results
demonstrate decreased protein expression of a gene, for example, RKIP, can serve as a
prognostic marker in PCa patients. Prostate 66: 248–256, 2006. # 2005 Wiley-Liss, Inc.
KEY WORDS: prognostic marker; RKIP; prostate cancer; metastasis suppressor gene;
tissue microarray
INTRODUCTION
Prostate cancer (PCa) metastases are the leading
causeof cancer-relateddeath amongAmericanmen [1].
A major challenge of treating PCa lies in accurately
distinguishing those histologically localized cancers,
which will undergo metastasis from those that will
remain indolent. Although there are abundant clinico-
pathological data regarding PCa, these data are
deficient in their utility to help predict the likelihood
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of cancer recurrence as evidenced by the observation
that 20%–30% of resected PCas recur although they are
theoretically curable based on prognostic factors [2,3].
The heterogeneity of CaP and its variable response to
treatment account for the dearth of prognostic markers
that can distinguish between tumors with high versus
low recurrence potential [4]. In order to improve the
ability to accurately predict which patients have the
greatest risk for developing aggressive PCa, the search
for new biochemical markers that are capable of
predicting PCa prognosis and, thus offer the opportu-
nity to provide optimal care for each PCa patient is of
great demand.
In a search for genes that regulate the metastatic
process in PCa, we performed gene array analysis
between non-metastatic and metastatic PCa cell lines.
This analysis revealed that Raf kinase inhibitor protein
(RKIP) expression was decreased in the metastatic
compared to non-metastatic cell line [5]. RKIP is a
soluble 23-kDa basic cytosolic protein that was initially
characterized as phosphatidylethanolamine-binding
protein (PEBP) [6,7]. RKIP suppresses mitogen-
activated protein kinase signaling by binding to Raf-1
and disrupting the physical interaction between Raf-1
and MEK [8]. In addition to its inhibition of Raf-1-
mediated activity, RKIP inhibits activation of both
the transcription factor nuclear factor kappa B (NF-kB)
[9] and G-coupled protein kinase 3 [10]. We pre-
viously demonstrated that RKIP fits the criteria of a
PCa metastasis suppressor gene (MSG) including the
ability to inhibit metastasis without an effect on
primary tumor growth in a murine model [11]. Taken
together, these observations suggest that RKIP has
potential as a molecular determinant of PCa progres-
sion and metastasis and thus provide a prognostic
value in PCa.
In this study, we utilized tissue microarrays to
evaluate the expression of RKIP protein in a wide
spectrum of prostate tissues in order to determine
comprehensively the extent and patterns of its expres-
sion in situ. In addition, with the aid of well-
documented clinical information for those patients we




The expression RKIP transcript in cancer tissueswas
obtained from meta-analysis of our recently estab-
lished cancer gene microarray meta-analysis public
database [12]. The normalized expression unit for RKIP
transcript was exported and subjected to statistical
analysis as previously described [12].
Case Selection and TissueMicroarrays
Cases of clinically localized PCa were identified
from a radical prostatectomy series at the University of
Michigan and caseswithPCametastaseswere obtained
from a Rapid Autopsy Program through the Michigan
Prostate SPORE Tissue Core (Table I). The autopsy
protocol and initial characterization of these cases have
recently reported [13]. Briefly, all the patients hadwell-
documented metastatic PCa. Autopsies were per-
formed within 4–6 hr of the patient’s death. Autopsy
revealed widespread PCa involving multiple sites. No
other primary malignancy was found. All tissue
procurement and analysis in this study was approved
by Institutional Review Board approval to procure and
analyze the tissues used. Standard demographic and
treatment history parameters were recorded.
To study the expression of RKIP in PCa,we used two
tissue microarrays (TMAs) that consisted of a total of
758 evaluable samples of non-neoplastic prostate
(n¼ 57), localized PCa (n¼ 79) and metastatic, hor-
mone-refractory PCa (n¼ 55). All 79 patients with
localized PCa underwent prostatectomy to treat their
localized disease. Gleason scores were 5 in 3 cases, 6 in
28 cases, 7 in 45 cases, and 8 in 3 cases. The metastatic
TMAs included PCa metastatic to the liver, lung, bone,
lymph node, brain, adrenal, and soft tissue. At least six
0.6-mm cores were taken from each sample. High-
density TMAswere assembled as previously described
[14,15]. Initial sections were stained for hematoxylin
and eosin to verify histology. The histological grade
was assessed using the Gleason grading system accor-
ding topreviouslydescribedmethods [16]. Clinical and
pathological variables were determined following
well-established criteria and maintained in a secure
relational database as previously described [17].
Immunohistochemistry and Evaluation
Standard avidin-biotin complex immunohistochem-
istry (IHC) was used. Briefly, antigen retrieval was
performed by steaming the slides for 15 min in 10 mM
sodium citrate buffer, pH 6.0, in amicrowave oven. The
slides were then incubated sequentially with primary
antibody, biotinylated secondary antibody, avidin-
biotin complex, and chromogenic substrate 3, 30-
diaminobenzidine. RKIP protein was detected using a
rabbit polyclonal anti-RKIP antibody (1:600 dilution,
Upstate Biotechnology, Lake Placid, NY). RKIP stain-
ing intensity was independently scored by two
genitourinary pathologists blinded to Gleason score,
tumor size, and clinical outcome. The staining was
scored as previously described [11,14]. Briefly, immu-
nostaining intensity was scored by a genito-urinary
pathologist as negative [1], weak [2], moderate [3], or
strong [4] based on the amount of stain detected. The
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pathologist evaluated the spectrum of staining inten-
sity in all the samples and then arbitrarily categorizes
the staining intensity into the various scores based on
the overall staining. The pathologist was blinded to
Gleason score, tumor size, or clinical outcome. On
average, four tissue cores were evaluated from each
case and the median value of all measurements from a
single case was used as the final score for subsequent
analysis. A total of 758 samples from non-neoplastic
tissue (n¼ 57), localized PCa (n¼ 79), and metastatic
PCa (n¼ 55) were examined.
Statistical Analysis
For analysis of gene microarray data, Student’s
t-test was used for pair-wise comparison of RKIP
transcript among benign prostate, localized PCa
and metastatic PCa samples as previously described
[18].
For statistical evaluation of immunohistochemistry
staining, RKIP staining was dichotomized into high
(Median RKIP staining 3) and low (median 2)
categories. The Mantel–Haenszel chi-square test was
applied to compare theRKIP staining in non-neoplastic
prostate, PCa, and metastases. This was followed by
chi-square test for post-hoc analysis. AP-value of<0.05
was considered significant. PSA recurrence was calcu-
lated from the date of surgical excision of the primary
tumor to the date of recurrence or the end of follow-up.
Kaplan–Meier analysis and Cox regression models
were applied to evaluate the predictive values of RKIP
and clinical parameters in differentiating recurrence
outcome. Statistical significance in the Coxmodels was
determined by the log-rank test.
TABLE I. Clinical Characteristics of 79 PatientsWhoseResected Prostate CancersWere Evlauted for RKIPExpressiona
Characteristic Total RKIP moderate/high RKIP negative/low P-value
Age (year) 60.3 7.7b 60.2 7.4 60.4 8.0 0.91c
Race
Caucasian 52 (66) 27 (66) 25 (66) 0.77d
African-American 19 (24) 9 (22) 10 (26)
Other 8 (10) 5 (12) 3 (8)
Length of follow-up (month) 50.0 28.5 59.9 22.0 39.3 30.9 0.0009a
Pre-prostatectomy PSA (ng/mL ) 9.0 8.8 8.7 7.7 9.3 9.9 0.76a
Maximum tumor diameter (cm) 1.6 0.7 1.6 0.7 1.5 0.6 0.40a
Gland weight (g) 51.8 16.6 53.7 19.3 49.8 13 0.29a
Gleason score—no. (%)
5 3 (4) 2 (5) 1 (3) 0.08e
6 28 (35) 19 (46) 9 (24)
7 45 (57) 18 (44) 27 (71)
8 3 (4) 2 (5) 1 (3)
DRE
Negative—no. (%) 49 (62) 27 (66) 22 (28) 0.47d
Positive—no. (%) 30 (38) 14 (34) 16 (42)
Pathologic stage—no. (%)
pT2 60 (76) 35 (85) 25 (66) 0.04d
pT3 19 (24) 6 (15) 13 (34)
Surgical margin status
Negative—no. (%) 53 (67) 31 (76) 22 (58) 0.09d
Positive—no. (%) 26 (33) 10 (24) 16 (42)
PSA-defined recurrence
No—no. (%) 58 (73) 36 (88) 22 (58) 0.003d
Yes—no. (%) 21 (27) 5 (12) 16 (42)
aCases were accrued from the years 1995–2001.
bData are presented as mean SD.
cThe P-valuewas calculated byWilcoxon’s rank-sum test for the comparison of the RKIPmoderate/high groupwith the RKIP negative/
low group.
dThe P-value was calculated by the Student’s t-test for the comparison of the RKIP moderate/high group with the RKIP negative/
low group.
eThe P-value was calculated by the Fisher’s exact test for the comparison of the RKIP moderate/high group with the RKIP negative/
low group.
PSA, prostate specific antigen; DRE, digital rectal examination.
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RESULTS
Analysis of gene expression data sets from our
recently established cancer gene microarray meta-
analysis public database [12] demonstrated decreased
RKIP expression with advanced cancer. Specifically,
Dhanasekaran et al. [18] investigated gene expression
patterns in non-cancerous prostate, localized PCa, and
metastatic PCa (Fig. 1). Our analysis of this dataset
revealed that RKIPmRNAexpressionwas significantly
lower in localized PCa than that in non-cancerous
prostate samples (P¼ 0.003, Student’s t-test). Further-
more, metastatic PCa has statistically significantly
lower RKIP mRNA expression relative to both non-
cancerous prostate tissues (P< 0.001, Student’s t-test)
and localized PCa (P¼ 0.021, Student’s t-test) (Fig. 1).
These data are in agreementwith our previous findings
in PCa cell lines [11] anddemonstrate that RKIPmRNA
expression declines with PCa progression.
To determine if changes in mRNA expression were
reflected by protein expression, we performed immu-
nohistochemistry for RKIP protein expression on
previously validated PCa tissue microarrays [13,14].
For benignprostate samples, themenhad ameanage of
58 years (range: 45–80). The patient demographics for
the men with primary tumors are described in detail in
Table I. For men with metastatic cancer, pre-prosta-
tectomy data were unavailable; however, in summary
there were 55 men with metastases with a mean age of
67 years (range: 40–84 years) approximately 36% had
prostatectomy; 60% had bilateral orchiectomy; 5% had
radiation therapy; and 100% had chemotherapy and
hormone ablation. PCa metastases that were examined
included skeletal, lymph node, hepatic, pulmonary,
dural, adrenal, splenic, spine, diaphragmatic, bladder,
seminal vesicle, testis, and pancreaticmetastases. RKIP
protein staining was cytoplasmic in all positive cases
(Fig. 2A,B). The prostatic origin of tumor cells expres-
sing RKIP was confirmed by positive IHC staining for
PSA (not shown). The intensity of RKIP staining was
dichotomized into two groups; weak/negative stain-
ing (score of 1 or 2) and moderate/strong staining
(score of 3 or 4). IHC analysis revealed that 95% of the
non-neoplastic prostate samples had moderate/strong
staining;whereas only 5%hadnegative/weak staining.
This differed for primary tumors of which 52% had
moderate/strong staining and 48%hadnegative/weak
staining. Finally, only 11%of themetastatic tumors had
moderate/strong staining; whereas, 89% had nega-
tive/weak staining (Fig. 2C). These data clearly
demonstrate that RKIP protein expression decreases
with overall PCa progression (P< 0.0001, Mantel–
Haenszel chi-square test). Furthermore, there was a
significant decrease in RKIP staining intensity between
benign prostate tissue compared to primary tumor
tissue (P< 0.0001, chi-square test). Similarly,metastatic
PCa had significantly lower expression of RKIP than
did clinically localized PCa (P< 0.0001, chi-square
test). These data suggest that RKIP expression could
be used to indicate the aggressiveness of an indivi-
dual’s PCa. To further confirm that the there was a
difference in RKIP expression between benign prostate
and primary tumors we identified those patients
in which we had paired benign tissue and primary
tumors. There were 38 patients with paired benign
prostate and primary tumors. The mean RKIP staining
was decreased in the primary tumors (mean¼ 2.9
0.37) compared to benign prostate tissues (mean¼
3.9 0.32; P< 0.001).
To begin to explore the prognostic utility of RKIP
expression in primary tumors, we initially evaluated
the association of RKIP protein expression with clinical
and pathological parameters. The clinical and patholo-
gic characteristics of the men with primary tumors are
shown in Table I. Themean age of the study population
was 60 years (7.7). After a mean follow-up of 50.0
months (28.5), 21 of the 79 patients (27 %) had PSA
recurrence. The 5- and 7-year disease-specific survival
rates for the entire cohort of patients were 72.8%
(5.26%) and 69.6% (5.91%), respectively. Clinical
stage was dichotomized by results of the digital rectal
examination (DRE) into palpable (or positive) and non-
palpable (or negative) groups. Pathological stage was
simplified to two classes, pT2 (organ-confined) and
pT3 (extraprostatic extension and/or seminal vesicle
Fig. 1. RKIPmRNAtranscriptlevels isdecreasedinprostate can-
cer (PCa). RKIP mRNA transcript levels in PCa progression mea-
sured using DNAmicroarrays as reported by Dhanasekaran et al.
[18].There were 22 cases of benign prostate, 59 cases of localized
PCa, 20 cases ofmetastatic PCa included in the study.Y-axis repre-
sents normalized expression units. P-value was calculated by using
theStudent’s t test.
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invasion). The natural logarithm of the preoperative
level of PSA (ln [PSA]) was used as previously describ-
ed [18]. RKIP showed the strongest association with
length of follow-up (P¼ 0.0009) and PSA recurrence
rate (0.003) (Table I). Specifically, RKIP levels were
inversely correlated with them, such that patients with
lower RKIP levels had earlier recurrence and higher
recurrence rate than those with higher RKIP expres-
sion. Additionally RKIP expression was inversely
correlated with pathological stage (P¼ 0.04), whereas
Gleason score were marginally associated with RKIP
levels. There was no significant correlation between
RKIP expression level and surgical margin (SM) status
(P¼ 0.09), tumor size (P¼ 0.40), gland weight (P¼
0.28), ln [PSA] (P¼ 0.59) or clinical stage (P¼ 0.47).
PSA failure (also termed PSA recurrence or bio-
chemical relapse) is defined as developing elevated
PSA levels greater than 0.2 ng/ml after radical
prostatectomy [19]. Patients demonstrating PSA failure
typically progress to developing distant metastases
anddyingof PCa [19]. To testwhetherRKIP canbeused
as apotential PCabiomarker topredict clinical outcome
in men treated with prostatectomy for clinically
localized PCa, we performed outcome analysis on 359
prostate samples from the 79 men with localized PCa
(each patient’s tumor is evaluated with an average of
4 samples). Kaplan–Meier analysis (Fig. 3A) revealed
that negative/weak RKIP staining predicted an earlier
PSA recurrence than moderate/strong RKIP expres-
sion. At 7 years of follow-up, only 13% of the patients
with moderate/strong staining tumors had PSA
recurrence, compared to 48% of the patients with
negative/weak staining tumors (P< 0.001, log rank).
These data demonstrate that RKIP expression is
prognostic for PSA recurrence.
To explore what clinical and pathological para-
meters could predict early PSA recurrence, we initially
performed a univariate analysis (Table II). At the
univariate level, tumor diameter, pathological stage,
SM status and ln [PSA] were directly associated with
PSA recurrence. In contrast, RKIP protein expression
was inversely associated with PSA recurrence. Gland
weight, Gleason score, and clinical stage were not
associated with PSA recurrence.
To examine the prognostic value of RKIP expression
independent of known clinical and pathologic param-
eters, multivariate analysis was performed (Table II).
To fit a multivariable Cox hazards regression model,
RKIP expression level along with tumor diameter,
pathological stage, SM status, ln [PSA], gland weight,
Gleason score, and clinical stage were included in the
model. The analysis indicated that RKIP expression
was the most significant predictor of PSA recurrence
followed by SM status and ln [PSA] (Table II). As in the
univariate analysis, RKIPwas inversely correlatedwith
PSA recurrence and SM status and ln [PSA] were
directly correlated with PSA recurrence. Although
tumor size and pathologic stage had a strong associa-
tion with PSA recurrence at the univariate level, they
had no independent association with outcome at the
Fig. 2. RKIPproteinisdownregulatedinPCa. (A)Representative
elements of a tissue microarray stained with anti-RKIP antibody.
Immunohistochemistry demonstrates strong staining of non-neo-
plastic prostate (A1-2), moderate staining in localized PCa (A3-4),
andabsentorweakstainingofmetastaticPCa(A5-6).Magnification
100. (B) RKIP expression is high in the secretary luminal cells of
non-neoplastic prostate (top), but absent in metastatic PCa (bot-




percentage of patients in each category.RKIP expression decreases
with increasing progression (P< 0.0001, Mantel^Haenszel chi-
square test).RKIP expression differs between all pairwise compari-
sons (P< 0.0001,chi-squareanalysis).
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multivariate level. A multivariate analysis of only the
three independent factors revealed that RKIP main-
tained significance as an independent factor, giving a
final best fit multivariate model predictive of PSA
recurrence that included the following terms and their
hazard ratios (95% CI; all at P¼ 0.0005, Cox regression
analysis): RKIP expression, 0.15, (0.05–0.44); ln [PSA],
6.73 (2.62–17.32) and surgical margin status 3.15 (1.68–
5.88). Based on this model, patients with a negative/
low RKIP expression are 85% more likely to have an
early PSA recurrence compared to those with moder-
ate/high RKIP expression. These results demonstrate
that expression of a MSG, namely RKIP, adds con-
siderably to a prognostic model for PSA recurrence.
The majority of CaP patients who undergo prosta-
tectomy have intermediate Gleason scores (i.e., scores
of 6–7) [20,21]. These Gleason scores are fairly non-
informative as it is difficult to determine prognosis of
patients that have tumors with these Gleason scores
[20–22]. Accordingly, to determine if RKIP expression
could provide additional prognostic information for
this subset of patients, we performed multivariate Cox
regression analysis of patients with Gleason scores 6 or
7 using clinical and pathological parameters. RKIP
level is a significantly better marker than ln [PSA] and
an as good amarker as surgical margin status (Fig. 3B).
Patients with tumors with Gleason score of 6 or 7 and
negative/low RKIP expression have a 79.2% greater
chance of PSA recurrence than those patients with
tumors that have moderate/high RKIP expression.
These results indicate that RKIP is a novel excellent
predictor of PSA recurrence in CaP patients with
Gleason scores of 6 and 7 and can provide greater
prognostic information than that of the currently used
Gleason score in this class of patients.
DISCUSSION
Our results demonstrate that RKIP expression is
decreased in PCa metastases and that immunohisto-
chemical assessment of RKIP in primary CaP provides
important independent prognostic information. Speci-
fically, in patients with tumors that express moderate/
high RKIP levels, the time to PSA recurrence is
significantly delayed compared to patients with tumor
that have negative/low RKIP expression. Approxi-
mately 50% of the patients’ primary tumors we
examined expressed negative/low RKIP levels, thus
indicating that these patients represent a significant
component of the PCa population undergoing
Fig. 3. Kaplan^MeierestimatesofPSArecurrence-freeprobabil-
ity for the patients with clinically localized PCa. (A) All patients:
Patients were stratified on the basis of moderate/high (RKIPþ) or
negative/low(RKIP)RKIPexpressionlevels.P-valuewascalculated
using the log-rank test. (B) Patients with Gleason score 6 or 7
tumors: Patients were stratified on the basis of moderate/high
(RKIPþ) or negative/low (RKIP) RKIP expression levels. P-value
wascalculatedusing thelog-rank test.
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prostatectomy. In our study cohort, the only other
independent prognostic indicators that we found were
surgical margins and ln [PSA].
A variety of MSGs has been evaluated for prognosis
in multiple cancers. However, until the current study,
there has been no clear documentation that decreased
expression of a MSG is prognostic for a cancer. For
example, theMSGKAI1was demonstrated not to be an
independent prognostic factor in endometrial cancer
[23], cervical cancer [24], or ovarian carcinoma [25]. In
fact, increased, as opposed to decreased, levels of a
KAI1 splice variant was shown to be an a poor
prognostic factor in gastric cancer [26]. Similarly,
increased expression of other MSGs KiSS-1 and nm23
have been shown to indicate a poor prognosis several
cancers [27–30] or aswith theMSGCD44 not to predict
outcome in cancer[31]; although in one studyCD44was
shown to predict survival [32]. In summary, decreased
expression of MSGs has not been clearly demonstrated
to be prognostic. Thus, our report provides an initial
example of a MSG involved in intracellular signaling
that is prognostic for cancer recurrence, which demon-
strates the importance of evaluating genes that have
decreased expression for prognostic value.
Currently usedmarkers for prognosis of PCa such as
preoperative serum PSA level, tumor stage, tumor
grade as measured by the Gleason score and surgical
margin are limited in their accuracy and prognostic
ability (reviewed in 33). For example, PSA screening
may in lead to the overdiagnosis and overtreatment of
patients with PCa [34]. In addition, PSA does not
correlate well with clinical outcome in patients with
PSA values of <10 ng/mL [35]. Similarly, the most
commonly used grading system in PCa, Gleason score
[36,37], ismost effective as aprognostic factor in tumors
with the low [2–4] or high [8–10] scores, but not very
effective in the more common tumors that have an
intermediate score [5–7] and show strikingly hetero-
geneous biological aggressiveness [33,38]. Thus devel-
opment of additional prognostic markers is an
important area of research. Results from the current
study demonstrate that RKIP is prognostic in patients
with PSA< 10 ng/ml andwith tumors that areGleason
score 6–7or havepositive surgicalmargins. Thus, RKIP
offers prognostic benefits above and beyond PSA,
Gleason score, and adds further information to those
tumors with positive surgical margins.
Radical prostatectomy is a definitive formof therapy
for clinically localized PCa [39]. After radical prosta-
tectomy, recurrence of the disease inmenwith negative
surgical margin suggests that undetected disease may
have spread beyond the prostate gland before surgery
[40,41]. Detecting this population of patients would
assist towards designing a therapeutic strategy, includ-
ing aggressive treatment. Our data demonstrate that
tumor RKIP expression levels can be used to predict
which of these patients will have early PSA recurrence,
and thus be used to provide a therapeutic recommen-
dation. It is worth noting that traditional Gleason score
did not statistically significantly stratify the risk of this
focused set of patients although its clinical implication
on prognostication has been demonstrated by many
groups [42,43]. We believe this was due to the fact that
the majority of the patients in this study had inter-
mediate Gleason scores (6 and 7) and intermediate
Gleason score is least sensitive prognostic marker to
stratify high risk patients [20–22].
Our finding that RKIP protein expression level in
PCa provides independent prognostic information,
given the novel metastasis suppressor activity of RKIP
in PCa, underscores that determining pathophysio-
logical mechanisms of cancer spread can lead to
TABLE II. Univariate andMultivariable COXHazards Analysis of Clinicopathological Parameters and Rkip Expression in 79
PatientsWith Prostate Cancer*
Variable
Univariate analysis Multivariate analysis
HR (95% CI) P-valuea HR (95% CI) P-valuea
RKIP 0.21 (0.08-0.58) 0.002 0.11 (0.03-0.38) 0.0005
Gleason score 1.80 (0.70-4.63) 0.23 0.38 (0.12-1.20) 0.10
Maximal tumor diameter 3.15 (1.34-7.42) 0.009 1.29 (0.46-3.60) 0.63
Pathological stage 3.70 (1.57-8.74) 0.003 1.33 (0.36-4.88) 0.66
SM 6.34 (2.54-15.80) <0.0001 6.72 (2.21-20.49) 0.0008
DRE 1.66 (0.71-3.91) 0.25 1.48 (0.43-5.07) 0.53
ln [PSA] 2.46 (1.39-4.36) 0.002 2.91 (1.33-6.37) 0.007
Gland weight 0.99 (0.96-1.02) 0.45 1.00 (0.96-1.03) 0.93
*HR, hazard ratio; CI, confidence interval; SM, surgical margin status; ln [PSA], natural logarithm of the pretreatment prostate-specific
antigen level (ng/mL).
aCox regression analysis. All statistical tests were two-sided.
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identification of molecular markers. These findings
should be tempered by the observation that there is
overlap of RKIP mRNA expression among normal,
primary tumors and metastases, which suggests that
RKIPmRNA expressionmay have limited use as a sole
prognostic factors in individuals; however, the data
indicate that low RKIP protein expression provides a
strong indication of early PSA failure. Accordingly,
assessment of RKIP expression may identify those
patients that could benefit from early aggressive
therapy.
ACKNOWLEDGMENTS
This work was supported by National Cancer
Institute Grants R01-CA098513 (to E.T.K.) and SPORE
1 P50 CA69568 (to E.T.K).
REFERENCES
1. Landis SH,Murray T, Bolden S,Wingo PA. Cancer statistics. CA
Cancer J Clin 1998;48(1):6–29.
2. Lerner SP, Seale-HawkinsC,CarltonCE Jr, Scardino PT. The risk
of dying of prostate cancer in patients with clinically localized
disease. J Urol 1991;146(4):1040–1045.
3. Schellhammer PF. Radical prostatectomy. Patterns of local
failure and survival in 67 patients. Urology 1988;31(3):191–197.
4. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M,
Han M, Epstein JI, Eisenberger MA, Walsh PC, Partin AW.
Contemporary identification of patients at high risk of early
prostate cancer recurrence after radical retropubic prostatect-
omy. Urology 2001;57(6):1033–1037.
5. Fu Z, Dozmorov I, Keller E. Osteoblasts produce soluble factors
that induce a gene expression pattern in non-metastatic prostate
cancer cells, similar to that found in bone metastatic prostate
cancer cells. Prostate 2002;51:10–20.
6. Perry AC, Hall L, Bell AE, Jones R. Sequence analysis of a
mammalian phospholipid-binding protein from testis and
epididymis and its distribution between spermatozoa and
extracellular secretions. Biochem J 1994;301(Pt 1):235–242.
7. Tohdoh N, Tojo S, Agui H, Ojika K. Sequence homology of rat
and human HCNP precursor proteins, bovine phosphatidy-
lethanolamine-binding protein and rat 23-kDa protein asso-
ciated with the opioid-binding protein. Brain Res Mol Brain Res
1995;30(2):381–384.
8. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F,
Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W.
Suppression of Raf-1 kinase activity and MAP kinase signalling
by RKIP. Nature 1999;401(6749):173–177.
9. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M,
Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf
kinase inhibitor protein interacts with NF-kappaB-inducing
kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell
Biol 2001;21(21):7207–7217.
10. Lorenz K, Lohse MJ, Quitterer U. Protein kinase C switches
the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 2003;
426(6966):574–579.
11. Fu Z, Smith PC, Zhang L, RubinMA,DunnRL, Yao Z, Keller ET.
Effects of raf kinase inhibitor protein expression on suppression
of prostate cancer metastasis. J Natl Cancer Inst 2003;95(12):
878–889.
12. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R,
Ghosh D, Barrette TR, Pandey A, Chinnaiyan AM. Oncomine:
A cancer microarray database and integrated data-mining
platform. Neoplasia 2004;6(1):1–6.
13. RubinMA, PutziM,Mucci N, SmithDC,WojnoK, Korenchuk S,
Pienta KJ. Rapid (‘‘warm’’) autopsy study for procurement of
metastatic prostate cancer. Clin Cancer Res 2000;6(3):1038–1045.
14. Perrone EE, Theoharis C, Mucci NR, Hayasaka S, Taylor JM,
Cooney KA, Rubin MA. Tissue microarray assessment of
prostate cancer tumor proliferation in African- American and
white men. J Natl Cancer Inst 2000;92(11):937–939.
15. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P,
Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP.
Tissue microarrays for high-throughput molecular profiling of
tumor specimens. Nat Med 1998;4(7):844–847.
16. Gleason DF. Classification of prostatic carcinomas. Cancer
Chemother Rep 1966;50(3):125–128.
17. Manley S, Mucci NR, De Marzo AM, Rubin MA. Relational
database structure to manage high-density tissue microarray
data and images for pathology studies focusing on clinical
outcome: The prostate specialized program of research excel-
lence model. Am J Pathol 2001;159(3):837–843.
18. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S,
Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation
of prognostic biomarkers in prostate cancer. Nature 2001;
412(6849):822–826.
19. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD,
Walsh PC. Natural history of progression after PSA elevation
following radical prostatectomy. Jama 1999;281(17):1591–1597.
20. AyalaG, Tuxhorn JA,Wheeler TM, FrolovA, Scardino PT,Ohori
M, Wheeler M, Spitler J, Rowley DR. Reactive stroma as a
predictor of biochemical-free recurrence in prostate cancer. Clin
Cancer Res 2003;9(13):4792–4801.
21. Ayala G, Wang D, Wulf G, Frolov A, Li R, Sowadski J, Wheeler
TM, Lu KP, Bao L. The prolyl isomerase Pin1 is a novel
prognostic marker in human prostate cancer. Cancer Res 2003;
63(19):6244–6251.
22. Dash A, Sanda MG, Yu M, Taylor JM, Fecko A, Rubin MA.
Prostate cancer involving the bladder neck: Recurrence-free sur-
vival and implications for AJCC stagingmodification. American
Joint Committee on Cancer. Urology 2002;60(2):276–280.
23. Liu FS, Dong JT, Chen JT, Hsieh YT, Ho ES, Hung MJ, Lu CH,
Chiou LC. KAI1 metastasis suppressor protein is down-
regulated during the progression of human endometrial cancer.
Clin Cancer Res 2003;9(4):1393–1398.
24. Schindl M, Birner P, Bachtiary B, Breitenecker G, Selzer E,
Oberhuber G. The impact of expression of the metastasis
suppressor protein KAI1 on prognosis in invasive squamous
cell cervical cancer. Anticancer Res 2000;20(6B):4551–4555.
25. Liu FS, Dong JT, Chen JT, Hsieh YT, Ho ES, Hung MJ. Frequent
down-regulation and lack of mutation of the KAI1 metastasis
suppressor gene in epithelial ovarian carcinoma. Gynecol Oncol
2000;78(1):10–15.
26. Lee JH, Seo YW, Park SR, KimYJ, KimKK. Expression of a splice
variant of KAI1, a tumor metastasis suppressor gene, influences
tumor invasion and progression. Cancer Res 2003;63(21):7247–
7255.
27. Ikeguchi M, Hirooka Y, Kaibara N. Quantitative reverse
transcriptase polymerase chain reaction analysis for KiSS-1
and orphan G-protein-coupled receptor (hOT7T175) gene
expression in hepatocellular carcinoma. J Cancer Res Clin Oncol
2003;129(9):531–535.
Raf Kinase Inhibitor Protein (RKIP) Predicts PSARecurrence 255
28. Niitsu N, Honma Y, Iijima K, Takagi T, Higashihara M, Sawada
U, Okabe-Kado J. Clinical significance of nm23-H1 proteins
expressed on cell surface in non-Hodgkin’s lymphoma. Leuke-
mia 2003;17(1):196–202.
29. MullerW, Schneiders A, Hommel G, Gabbert HE. Expression of
nm23 in gastric carcinoma: Association with tumor progression
and poor prognosis. Cancer 1998;83(12):2481–2487.
30. Szumilo J, Skomra D, Chibowski D, Dabrowski A, Wallner G,
Maciejewski R. Immunoexpression of nm23 in advanced
esophageal squamous cell carcinoma. Folia Histochem Cytobiol
2002;40(4):377–380.
31. MasudaM, Kuratomi Y, Shiratsuchi H, Nakashima T, Naonobu
K, Komiyama S. Decreased CD44H expression in early-stage
tongue carcinoma associates with late nodal metastases follow-
ing interstitial brachytherapy. Head Neck 2000;22(7):662–665.
32. Gonzalez-Moles MA, Bravo M, Ruiz-Avila I, Esteban F,
Rodriguez-Archilla A, Gonzalez-Moles S, Arias B. Adhesion
molecule CD44 as a prognostic factor in tongue cancer. Antic-
ancer Res 2003;23(6D):5197–5202.
33. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ,
Oesterling JE, ScardinoPT, Pearson JD.Combinationof prostate-
specific antigen, clinical stage, and Gleason score to predict
pathological stage of localized prostate cancer. A multi-institu-
tional update. Jama 1997;277(18):1445–1451.
34. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann
PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen
screening: Lessons from US prostate cancer incidence trends.
J Natl Cancer Inst 2002;94(13):981–990.
35. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM.
Preoperative serum prostate specific antigen levels between 2
and 22 ng/ml correlate poorly with post-radical prostatectomy
cancer morphology: Prostate specific antigen cure rates
appear constant between 2 and 9 ng/ml. J Urol 2002;167(1):
103–111.
36. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic
adenocarcinoma by combined histological grading and clinical
staging. J Urol 1974;111(1):58–64.
37. Epstein JI, PizovG,Walsh PC.Correlation of pathologic findings
with progression after radical retropubic prostatectomy. Cancer
1993;71(11):3582–3593.
38. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN,
Hoedemaeker RF, Kranse R. Prostate cancer detection at low
prostate specific antigen. J Urol 2000;163(3):806–812.
39. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP,
Barrett DM. Long-term (15 years) results after radical prosta-
tectomy for clinically localized (stage T2c or lower) prostate
cancer. J Urol 1994;152(5 Pt 2):1850–1857.
40. HanM, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term
biochemical disease-free and cancer-specific survival following
anatomic radical retropubic prostatectomy. The 15-year Johns
Hopkins experience. Urol Clin North Am 2001;28(3):555–565.
41. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA
doubling time as a predictor of clinical progression after
biochemical failure following radical prostatectomy for prostate
cancer. Mayo Clin Proc 2001;76(6):576–581.
42. PettawayCA. Prognosticmarkers in clinically localized prostate
cancer. Tech Urol 1998;4(1):35–42.
43. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of
Gleason score, prostate specific antigen, seminal vesicle and
margin status to predict biochemical failure after radical
prostatectomy. J Urol 2001;165(1):119–125.
256 Fuet al.
